Introduction

Craneware plc (LSE:CRW) is a healthcare-technology company that helps US hospitals and health systems improve their financial performance, margins and operational efficiency. With a highly recurring, subscription-based Revenue model delivered through its Trisus cloud platform, Craneware (CRW) has built a reputation as a quality compounder on London’s growth market. Strong recent results, rising Recurring Revenue and a growing Dividend have reinforced that reputation.

Why Craneware (CRW) is in focus now

Craneware (CRW) is in focus after delivering robust full-year results featuring a sharp rise in profit, continued growth in annual recurring revenue (ARR) and another dividend increase, followed by resilient interim results and a share buyback. The company’s exposure to the large US healthcare market, its sticky software model and its strong cash generation have made it a favoured name among investors seeking durable, recurring-revenue growth, even as it navigates disruption in certain US healthcare programmes.

Business overview

Craneware provides software and analytics that help US healthcare providers manage pricing, billing, costs and margins. Its Trisus cloud ecosystem delivers revenue and Margin intelligence, advanced analytics and chargemaster management tools, helping hospitals optimise their financial performance and comply with complex US healthcare regulations. The business model is heavily subscription-based, generating high levels of recurring revenue with strong retention. Although UK-listed, Craneware’s customers and revenues are overwhelmingly in the United States.

Latest Earnings explained

For the financial year ended 30 June 2025, Craneware reported revenue up about 9% to roughly US$205.7m, with annual recurring revenue climbing about 7% to around US$184m and net revenue retention improving to about 107%. Adjusted EBITDA rose about 12% to roughly US$65.3m, a margin of about 32%, and profit before tax jumped about 52% to around US$24m. For the first half of FY2026 (the six months to 31 December 2025), revenue rose about 6% to roughly US$106m, with adjusted EBITDA of around US$33.4m and ARR of about US$184.3m, alongside continued strong cash generation despite some disruption in a US rebate programme.

Revenue, profit, margins, Cash Flow and Balance Sheet

Craneware’s financial model is attractive: high recurring revenue, strong margins and good cash conversion. The improvement in net revenue retention to about 107% indicates that existing customers are spending more over time, a key driver of durable growth. Adjusted EBITDA margins of around 32% reflect the scalability of the software model, and the sharp rise in profit before tax shows Operating Leverage and lower financing costs. The company’s strong balance sheet and cash generation have supported both a rising dividend and a US$25m share buyback announced alongside its interim results.

What management said

Management has emphasised the quality of Craneware’s recurring-revenue model, the strength of its cash generation and the resilience of the business despite disruption in certain US healthcare programmes. Commentary highlighted growth in ARR and improving net revenue retention as evidence of customer stickiness and expansion, and pointed to the Trisus platform as central to the company’s strategy. The decisions to raise the dividend and launch a buyback reflected management’s confidence in the company’s financial strength and outlook.

Latest news and announcements

Recent developments include the strong FY25 results with the 52% profit increase and 10% dividend rise, and the H1 FY26 interim results showing continued revenue and ARR growth, an 11% increase in the Interim Dividend and a US$25m share buyback. Craneware also noted disruption in a US rebate programme, which it has managed while continuing to grow. The company’s progress in cross-selling its Trisus platform to existing customers is a recurring theme in its updates.

Share-price performance and market reaction

Craneware (CRW) shares have traded around 1,508p. The shares have been supported by the company’s consistent delivery, recurring-revenue model and rising Shareholder returns. As a software business reliant on the US healthcare market, the shares can be affected by US healthcare policy and budgetary developments, by currency movements between the US dollar and sterling, and by sentiment towards growth and software stocks. The quality of the model has generally supported a premium rating.

Growth drivers

The main growth drivers for Craneware (CRW) are the expansion of its ARR through new customers and increased spending by existing ones, reflected in net revenue retention above 100%; the cross-selling of additional Trisus modules and analytics; and the structural need for US hospitals to improve financial performance amid cost and reimbursement pressures. The scalability of the software model supports margin expansion, and strong cash generation funds both Investment and shareholder returns.

Key risks for investors

Craneware faces risks including its heavy reliance on the US healthcare market, which exposes it to US healthcare policy, regulation and reimbursement changes, as the rebate-programme disruption illustrates. Currency movements between the US dollar and sterling affect reported results and dividends. Competition in healthcare software is significant, and customer budget pressures could affect spending. The shares’ premium rating means they could be vulnerable if growth slows. Execution on product development and cross-selling is important to sustaining ARR growth.

Dividend position

Craneware (CRW) is a progressive dividend payer, having raised its full-year FY25 dividend by about 10% to 32p per share (with a final dividend of 18.5p), and subsequently lifting its interim dividend by about 11%. Combined with the US$25m share buyback, this reflects strong cash generation and management’s confidence. While the Yield is modest given the company’s growth and quality characteristics, the rising dividend adds an income element to the investment case.

Outlook for the next 6–12 months

Over the next 6–12 months, the focus will be on continued ARR growth, net revenue retention, and the conversion of the Trisus platform opportunity, alongside managing any further disruption in US healthcare programmes. Investors will watch margin progression and cash generation, and the progress of the share buyback. US healthcare policy and reimbursement trends will be important external factors. The recurring-revenue model provides a degree of visibility and resilience.

Investor takeaway

Craneware (CRW) is a high-quality, recurring-revenue healthcare-software business with strong margins, growing ARR, rising shareholder returns and exposure to the large US healthcare market. The investment case rests on continued ARR growth and platform expansion, balanced against US healthcare-policy risk, currency exposure and a premium valuation. This article is for information only and is not financial advice; investors should do their own research.